Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nightstar Therapeutics plc

https://www.nightstartx.com/

Latest From Nightstar Therapeutics plc

Stock Watch: Biogen, Blood In The Water

When almost everything that could go wrong has gone wrong at a company, the proposition of it turning acquirer may meet with some resistance from its proposed targets and their investors.

Stock Watch M & A

Five (Non-COVID) Clinical Trial Misses Of 2021

The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking. 

Clinical Trials Companies

Five (Non-COVID) Clinical Trial Misses Of 2021

The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.

Scrip Perspectives Clinical Trials

AGTC Moves Past Biogen With Ophthalmic Gene Therapy

AGTC hopes to gain the first approval in X-linked retinitis pigmentosa for its gene therapy AGTC-501, now in a Phase II/III study. It also is advancing development in achromatopsia, another unmet medical need.

Gene Therapy Rare Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Nightstar Therapeutics Limited
    • NightstaRx Ltd
UsernamePublicRestriction

Register